POSTN

Chenyang Zhang, Si Chen, Chenghui Qian, Wanqi Lv, Qian Zhang, Yanjin Wang, Yuqiong Wu, Xue Liu

Abstract read

In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chenyang Zhang *Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Minhang, Shanghai 201102, P.R. China.

Si Chen *Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Minhang, Shanghai 201102, P.R. China.

Chenghui Qian *Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Minhang, Shanghai 201102, P.R. China.

Wanqi LvShanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Minhang, Shanghai 201102, P.R. China.

Qian ZhangDepartment of Oral Pathology, Dalian Stomatological Hospital, Shahekou, Dalian 116021, P.R. China.

Yanjin WangShanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Minhang, Shanghai 201102, P.R. China.

Yuqiong WuShanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Minhang, Shanghai 201102, P.R. China.

Xue LiuShanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Fudan University, Minhang, Shanghai 201102, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinoma‑associated fibroblasts (CAFs) exhibit notably heterogeneity and are closely implicated in immune checkpoint blockade (ICB) resistance in head and neck squamous cell carcinoma (HNSCC). However, the specific subtypes and mechanisms involved remain to be elucidated. By analyzing two single‑cell RNA sequencing datasets (GSE103322 and GSE139324) and The Cancer Genome Atlas (TCGA)‑HNSCC dataset, two distinct fibroblasts subtypes were identified: Perostin (POSTN)

Indexed as

Cancer-Associated FibroblastsExtracellular VesiclesMacrophagesPeriostinBone Morphogenetic Protein 4Cell Adhesion MoleculesHumansMacrophage ActivationSignal TransductionSmad ProteinsTHP-1 CellsTumor MicroenvironmentBMP4 protein, humanBone Morphogenetic Protein 4Cell Adhesion MoleculesPeriostinPOSTN protein, humanSmad Proteinsmacrophage M2 polarizationperostin+ fibroblastssmall extracellular vesicles

Identifiers

PMID41645751

DOI10.3892/or.2026.9067

PMCPMC12891935

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.